Abstract
Atopic dermatitis (AD) management may require the use of a systemic medication such as abrocitinib (Cibinqo), which is a targeted Janus kinase (JAK) 1 inhibitor that suppresses aberrant T helper 2 (Th2) signaling present in AD pathogenesis. Unique features that distinguish abrocitinib from other systemic treatments for AD include its oral route of administration, once daily dosing, approval for use in all adults, and lack of conjunctivitis as a reported side effect in clinical trials. Notably, seven phase II and phase III clinical trials have each shown that abrocitinib achieved superior clinical efficacy compared to placebo as measured through disease severity scales and worst reported itch—including one clinical trial that showed improved short-term AD outcomes compared to dupilumab use. Coupled with minimal lab monitoring once the drug is initiated, abrocitinib can be considered as a systemic option in patients with moderate-to-severe AD to achieve their treatment goals.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ständer S. Atopic Dermatitis. Ropper AH, editor. N Engl J Med [Internet]. 2021 Mar 25 [cited 2022 Dec 23];384(12):1136–43. https://pubmed.ncbi.nlm.nih.gov/33761208/
Lynde CW, Bourcier M, Gooderham M, Guenther L, Hong CH, Papp KA, et al. A treatment algorithm for moderate to severe Atopic dermatitis in adults. J Cutan Med Surg [Internet]. 2018;22(1):78–83. [cited 2022 Dec 23] Available from: https://pubmed.ncbi.nlm.nih.gov/29082775/
Linder C, Shourick J, Touhouche AT, Giordano-Labadie F, Severino-Freire M, Borjesson C, et al. Analysis of non-responders to dupilumab in clinical practice: a cohort study. J Eur Acad Dermatol Venereol [Internet]. 2021;35(3):e192–4. [cited 2022 Dec 23]. Available from: https://pubmed.ncbi.nlm.nih.gov/32870543/
Vazquez ML, Kaila N, Strohbach JW, Trzupek JD, Brown MF, Flanagan ME, et al. Identification of N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases. J Med Chem [Internet]. 2018;61(3):1130–52. [cited 2022 Dec 23]. Available from: https://pubmed.ncbi.nlm.nih.gov/29298069/
Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol [Internet]. 2021;148(4):927–40. [cited 2022 Dec 23]. Available from: https://pubmed.ncbi.nlm.nih.gov/34437922/
Szalus K, Trzeciak M, Nowicki RJ. JAK-STAT inhibitors in atopic dermatitis from pathogenesis to clinical trials results. Microorganisms [Internet]. 2020;8(11):1–14. [cited 2022 Dec 23]. Available from: /pmc/articles/PMC7694787/
Perche PO, Cook MK, Feldman SR. Abrocitinib: a new FDA-approved drug for moderate-to-severe atopic dermatitis. Ann Pharmacother [Internet]. 2022;57(1):86–98. [cited 2022 Dec 23]. https://doi-org.ucsf.idm.oclc.org/101177/10600280221096713. Available from: https://journals-sagepub-com.ucsf.idm.oclc.org/doi/10.1177/10600280221096713?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed
Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis [Internet]. 2021;80(1):71–87. [cited 2022 Dec 23]. Available from: https://pubmed.ncbi.nlm.nih.gov/33158881/
Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol [Internet]. 2021;22(5):693–707. [cited 2022 Dec 23]. Available from: https://pubmed.ncbi.nlm.nih.gov/34406619/
Alves C, Penedones A, Mendes D, Batel MF. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis. Eur J Clin Pharmacol [Internet]. 2022;78(12):1923–33. [cited 2022 Dec 23]. Available from: https://link.springer.com/article/10.1007/s00228-022-03400-4
CIBINQO Indications and Usage (abrocitinib) | Pfizer Medical Information—US [Internet]. [cited 2022 Dec 23]. https://www.pfizermedicalinformation.com/en-us/cibinqo-0/indications-usage
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med [Internet]. 2022;386(4):316–26. [cited 2023 Jan 10]. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2109927
Le M, Berman-Rosa M, Ghazawi FM, Bourcier M, Fiorillo L, Gooderham M, et al. Systematic review on the efficacy and safety of oral janus kinase inhibitors for the treatment of atopic dermatitis. Front Med [Internet]. 2021;8:682547. [cited 2023 Jan 4]. Available from: /pmc/articles/PMC8440866/
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Jin, J.Q. et al. (2024). Treatment of AD with Abrocitinib. In: Brownstone, N., Liao, W., Bhutani, T. (eds) Clinical Cases in Atopic Dermatitis. Clinical Cases in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-031-52147-8_15
Download citation
DOI: https://doi.org/10.1007/978-3-031-52147-8_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-52146-1
Online ISBN: 978-3-031-52147-8
eBook Packages: MedicineMedicine (R0)